Vir Biotechnology Appoints Elliott Sigal, M.D., Ph.D. to Board of Directors

SAN FRANCISCO, July 10, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Elliott Sigal, M.D., Ph.D., to its board of directors. Dr. Sigal formerly served as Executive Vice President, Chief Scientific Officer and President of Bristol-Myers Squibb Company (BMS) Research and Development (R&D), where he played an instrumental role in bringing 14 new medicines to patients in need.

Click to view original post